US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
MKB Nedsense (0ML7) 銘柄情報

MKB Nedsense (0ML7)

0.159

0.00

(0.00%)

終了 6月28日 12:30AM

MKB Nedsense (0ML7) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.159

( - )

買値

0.159

売値

0.159

出来高

0.00

0.00 日の範囲 0.00

0.159 52 週間の範囲 0.159

時価総額

前日終値

0.159

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

43,915 €

発行済株式数

100,000,000

配当利回り

0.04

PER

-24.66

1 株当たり利益 (EPS)

-0

歳入

-220k

純利益

-305k

MKB Nedsense N.V. engages in the financing and lending of funds to natural persons and legal entities. It offers guarantees and/or other securities to third parties for its obligations and/or for obligations for companies in its investment portfolio. The company was formerly known as Nedsense Enterp... MKB Nedsense N.V. engages in the financing and lending of funds to natural persons and legal entities. It offers guarantees and/or other securities to third parties for its obligations and/or for obligations for companies in its investment portfolio. The company was formerly known as Nedsense Enterprises N.V. amd changed its name to MKB Nedsense N.V. in February 2018. MKB Nedsense N.V. was founded in 1999 and is based in Bussum, the Netherlands. 詳細を表示

セクター

-

業界

-

ウェブサイト

www.nedsense.nl

本社

Bussum, Netherlands

設立

1999

MKB Nedsense is listed in the sector of the ロンドン証券取引所 with ticker 0ML7. The last closing price for MKB Nedsense was 0.16 €. Over the last year, MKB Nedsense shares have traded in a share price range of 0.159 € to 0.159 €.

MKB Nedsense currently has 100,000,000 shares in issue. The market capitalisation of MKB Nedsense is 15.90 € million. MKB Nedsense has a price to earnings ratio (PE ratio) of -24.66.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0.159	0.159	0.159	605	0.159	DE
52	0	0	0.159	0.159	0.159	1946	0.159	DE
156	0	0	0.159	0.159	0.159	610	0.159	DE
260	0	0	0.159	0.159	0.159	353	0.159	DE

0ML7 - Frequently Asked Questions (FAQ)

What is the current MKB Nedsense share price?

The current share price of MKB Nedsense is 0.159 €

How many MKB Nedsense shares are in issue?

MKB Nedsense has 100,000,000 shares in issue

What is the market cap of MKB Nedsense?

The market capitalisation of MKB Nedsense is EUR 15.9M

What is the 1 year trading range for MKB Nedsense share price?

MKB Nedsense has traded in the range of 0.159 € to 0.159 € during the past year

What is the PE ratio of MKB Nedsense?

The price to earnings ratio of MKB Nedsense is -24.66

What is the cash to sales ratio of MKB Nedsense?

The cash to sales ratio of MKB Nedsense is -34.18

What is the registered address of MKB Nedsense?

The registered address for MKB Nedsense is Brediusweg 33, Bussum, Noord-Holland, 1400 AA

What is the MKB Nedsense website address?

The website address for MKB Nedsense is www.nedsense.nl

The-Shadow

The-Shadow 6分前

The 2013–2015 Inflection Point: During this specific window, the global video distribution landscape was in a state of high transition. The industry was moving toward 4K and specialized high-fidelity streaming, but the hardware decoding ecosystems for standard formats were not yet entirely locked do

BBANBOB

BBANBOB 6分前

Just get us our FCNCA stock and we will figure out what too do with it SELL It or HOLD IT

Wallstreeter$$$

Wallstreeter$$$ 9分前

And hw many of those before were prepped and submitted by Smith of Hogan Lovells!?.....oh right the ans is zero! Pretty sure he knows a whole lot more abt what the FDA wants compared to MK just winging it in the past.

brooktrail1933

brooktrail1933 11分前

Of course they could, but here's the quote from Beartrap:

"IMHO, the real question now is will Dr. Bosch release the decision on the MAA at this presentation?"

mm41

Introductory Macroeconomic Overview
When WE published our preliminary reviews of NVIDIA Corporation (Ticker: NVDA) in April and May 2026, our primary objective was to expose the superficiality of the consensus market narrative. Today, in late June 2026, as market euphoria is mechanically sust

namtae

namtae 13分前

How many shares did you top off in the 70s and 80's?

Must be quite a bit according to your posting history

learningcurve2020

learningcurve2020 13分前

All the PLD data in the world isn’t going to tell them why L worked on a small number of patients. LP was likely told to figure that out first then resume trials. That’s also why LL became a SA. Without that information, another trial, and combined with reasonable cost, UK Marketing approval at th

capgain

capgain 14分前

Same here, and what a great price! He sure seems like it.

walterc

walterc 15分前

they were accumulated over severall weeks by the market makers

mm41

Calling this 'fear-based' is a convenient way to dismiss a forensic balance sheet analysis. You’re trading off consensus narratives; I’m trading off what’s actually recorded in the filings. Let’s address your 'scrutiny':

On Receivables & Cash Flow: You claim DSO is 'stable' and 'no ve

BIOChecker4

BIOChecker4 18分前

Right, and Ern and the 70 other AD patients you claim are still alive and taking Blarcamesine every day even though the compassionate use program ended in 2024. Are these folks mixing their own batches of Blarcamesine in Ern’s basement?

Doc logic

Doc logic 19分前

brazen22,

Thank you for supplying that direct quote. Again, “authorities” is plural so the warning is warranted because FDA only “accepts” the SAP hence the caution that one or more of those “authorities” may not grant product APPROVAL based on that approach. This statement covers t

BBANBOB

BBANBOB 20分前

Could go on forever but I seriously doubt that it will

DA BOYZ which have enough money to seriously stir the POT want their money as well

Wallstreeter$$$

Wallstreeter$$$ 21分前

Anyone.....has the company ever indicated they're looking at uplisting?

BBANBOB

BBANBOB 22分前

I have said on multiple occasions here that IF none OF THE dates PRODUCE ANYTHING, then I will wait for closing of the "R" before I make any decisions as to if anything is or IS NOT coming back.
CBOA( indicated that we MAY VERY WELL HAVE TO WAIT for the "R" to be lifted before anything takes

theswordman

theswordman 22分前

Apologies. Do you find Hoffman is not doing as well as micky mouse mulholland and sidekick weed/wine.??

The 3 rounds of financing were linked .
So for #1-- Did you not like the Yorkville deal because of there are no warrants, derivatives, or other share classes asso

flipper44

flipper44 22分前

Scientific analysis with patient level data is not a distraction. If you can’t follow, spend that upcoming half hour on your rowing machine.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177739827

SSKILLZ1

SSKILLZ1 23分前

Pick 4 Contest #24 Contest Week 6 Results In

Hope everyone enjoys the stats and has fun in the contest. Hope this helps.

https://investorshub.advfn.com/Pick-4-Contest-No-24-50633

NotTheRealBeeny

NotTheRealBeeny 23分前

I bet that's true of the others that recently showed up as well. They'll all disappear at the same time too. I'm sure it's coincidence.

SSKILLZ1

SSKILLZ1 24分前

Pick 4 Contest #24 Contest Week 6 Results In

Hope everyone enjoys the stats and has fun in the contest. Hope this helps.

https://investorshub.advfn.com/Pick-4-Contest-No-24-50633

biotechinvestor1

biotechinvestor1 24分前

I agree. The sooner the better. Also while they are at it, they should replace the VP of IR who came from Antares. In over 30 years of experience as an investor in biopharma, I have not seen one with such poor performance.

Wallstreeter$$$

Wallstreeter$$$ 25分前

Have to agree with you on that one. Its very possible IDE approval may not have a huge effect on the PPS, but....if the right peeps hop onboard it could get real crazy on news. I guess w'ell see soon enuf.

ZZZ888

ZZZ888 26分前

gitreal

gitreal 26分前

He does it as a public service. Purely voluntary! Except for the free shares.

murrayhill

murrayhill 26分前

The Tokai "335" caught my eye;
that first guy was a guitar player, imo.

SDAX Net Return

Mongolian Mining

Adtiger Corporations

Gatwick Funding

CRC vs Sterling

International Consolidat...

Barclays Bank Plc Fixed ...

Xtrackers IIJ P Morgan U...

Matsui Secs Uspn Adr (PK)

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。